Company Encyclopedia
View More
name
Supernus Pharma
SUPN.US
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS.
4.499 T
SUPN.USMarket value -Rank by Market Cap -/-

Financial Score

07/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking58/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.86%D
    • Profit Margin-2.80%D
    • Gross Margin74.84%A
  • Growth ScoreC
    • Revenue YoY4.54%C
    • Net Profit YoY-132.02%E
    • Total Assets YoY5.74%B
    • Net Assets YoY4.22%C
  • Cash ScoreD
    • Cash Flow Margin-3565.09%E
    • OCF YoY4.54%C
  • Operating ScoreC
    • Turnover0.49C
  • Debt ScoreB
    • Gearing Ratio26.07%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Supernus Pharmaceuticals to Present at Bank of America Securities CNS Therapeutics Virtual Conference

    Supernus Pharmaceuticals will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025. CEO Jack A. Khattar will speak at 3:20 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 60 days. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    SUPN
    +1.29%
    Reuters·
    US
    SUPN
    +1.29%

    Chmn Newhall III Acquires 15,000 Of Supernus Pharmaceuticals Inc [SUPN]

    Charles W. Newhall III, Chairman of Supernus Pharmaceuticals Inc, acquired 15,000 shares of the company at $12.98 each, totaling $194,700. This transaction was filed with the SEC on November 24, 2025. Newhall's ending holdings are now 119,644 shares. The shares were exercised 8.7 years after the vest date and 3.3 months before expiration.

    Reuters·
    US
    SUPN
    +1.29%
    Reuters·
    US
    SUPN
    +1.29%

    Supernus Pharmaceuticals to Join Piper Sandler Annual Healthcare Conference

    Supernus Pharmaceuticals Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, featuring a fireside chat with CEO Jack A. Khattar. The information was originally published by Supernus Pharmaceuticals via GlobeNewswire.

    Reuters·
    US
    SUPN
    +1.29%
    Reuters·
    US
    SUPN
    +1.29%

    Supernus Pharmaceuticals Joins Jefferies Global Healthcare Conference in London

    Supernus Pharmaceuticals Inc. will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on November 17, 2025. President and CEO Jack A. Khattar will represent the company at the event.

    Reuters·
    US
    SUPN
    +1.29%
    Reuters·
    US
    SUPN
    +1.29%

    Supernus Pharma | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 192.1 M

    LB filings·
    US
    SUPN
    +1.29%
    LB filings·
    US
    SUPN
    +1.29%
    © 2025 Longbridge｜Disclaimer